Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Clinical trial NCT07176650 · RECRUITING
Trial details
- NCT number
- NCT07176650
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-25
- Primary completion
- 2026-12-01
- Enrollment
- 246
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.